PhaseBio Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

PhaseBio Pharmaceuticals

14/05/2021 01:46

* PhaseBio Pharmaceuticals Inc  PHAS.OQ  reported a quarterly
adjusted loss of 87 cents​​ per share for the quarter ended
in March. The mean expectation of five analysts for the quarter
was for a loss of 73 cents per share.
* Reported revenue was zero​;  analysts expected $26.67
thousand. 
* PhaseBio Pharmaceuticals Inc's reported EPS for the quarter
was a loss of 87 cents​.
* The mean earnings estimate of analysts had fallen by
about 5.9% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* PhaseBio Pharmaceuticals Inc shares had fallen by 16.5% this
quarter and lost 14.0% so far this year.
* The company reported a quarterly loss of $27.36 million.
* Wall Street's median 12-month price target for PhaseBio
Pharmaceuticals Inc is $18.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 14 at 12:46 a.m. GMT.
​All figures in US dollars